NSD3
NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.
Overview
Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression.
Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.19, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Lung Squamous Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.
- 1 · What it is
NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.
- 2 · What goes wrong in cancer
Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2.
- 3 · How drugs use it
No product in this corpus aims at NSD3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:12767 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BZ95 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000147548 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: colorectal cancer 0.51, skin cancer 0.52, breast cancer 0.54 (GraphQL API, CC0)); IntOGen NSD3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression. Location: Nucleus; Chromosome (UniProt). Locus 8p11.23 (HGNC).
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575)
- Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUSC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"NSD3" OR ABSTRACT:"NSD3" OR TITLE:"nuclear receptor binding SET domain protein 3" OR ABSTRACT:"nuclear receptor binding SET domain protein 3" OR TITLE:"Histone-lysine N-methyltransferase NSD3" OR ABSTRACT:"Histone-lysine N-methyltransferase NSD3" OR TITLE:"FLJ20353" OR ABSTRACT:"FLJ20353" OR TITLE:"WHISTLE" OR ABSTRACT:"WHISTLE" OR TITLE:"KMT3F" OR ABSTRACT:"KMT3F") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NSD3, not a curated reading list.